Sionna Therapeutics Inc(SION) - 2025 Q1 - Quarterly Results

On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Exhibit 99.1 Sionna Therapeutics Reports First Quarter 2025 Financial Results Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter Strong cash position following completed upsized IPO, with approximately $354.7 million in cash ...